Skip to Content
Biotechnology

It Costs $30 to Make a DIY EpiPen, and Here’s the Proof

The medical maker collective Four Thieves Vinegar made an “EpiPencil” for a tiny fraction of what the EpiPen manufacturer Mylan charges.
September 20, 2016

The recent furor over the drug company Mylan jacking up the price of lifesaving EpiPens has brought out the biohackers. A team of DIY enthusiasts calling themselves Four Thieves Vinegar have published plans that will allow anyone to build a device to self-inject epinephrine on the cheap.

EpiPens are meant as a last-ditch measure to ward off anaphylaxis—a potentially fatal allergic reaction that can result from exposure to anything from peanuts to insect stings. The drug itself is over 100 years old, but the device makes it easy for anyone to inject, which is an attractive proposition when flirting with death.

The pharmaceutical company Mylan, which is the only manufacturer of the device, was recently shown to have raised the prices of a single device from $57 to $318—that’s a 461 percent increase—since acquiring rights to it in 2007. The backstory is a bizarre tale that involves corporate greed, Congress, and Sarah Jessica Parker. Sadly, the cost prevents some people from having access to an incredibly reliable way to treat anaphylaxis.

It may not look like much, but Four Thieves Vinegar claims that the $30 home-brew EpiPencil works just as well as the official $300 EpiPen.

There are several reasons why nobody else has built an alternative to the EpiPen, among them patent protection, fear of creating a device that doesn’t work reliably, and a regulatory process that makes getting products to market incredibly difficult.

Mylan did bow (a little) to public pressure, announcing a new generic EpiPen that costs $150 for a single device. But industry insiders have suggested that the components of an EpiPen cost only around $30.

And Four Thieves Vinegar, a collective that was founded to create tools for DIY medicine, has now shown that to be accurate.

The group has published a video and instructions online in which it demonstrates how to build a home-brew version of the device. They call it the EpiPencil. The team claims that it can “be built entirely using off-the-shelf parts, for just over $30.” It pairs an existing auto-injector for diabetes sufferers with regular hypodermic needles. There is, of course, the small matter of sourcing the drug that puts the “epi” in the EpiPencil—but that can be obtained under prescription or online from a chemical supplier.

It’s worth noting that while it may be possible to make such a device at home, it’s completely unregulated. Using one to treat a person for anaphylaxis would not necessarily be a good idea. But as proof that Mylan’s pricing is inflated, there’s no denying its validity.

(Read more: Stat, The Guardian, NBC)

Deep Dive

Biotechnology

He Jiankui
He Jiankui

The creator of the CRISPR babies has been released from a Chinese prison

He Jiankui created the first gene-edited children. The price was his career. And his freedom.

Aging Clocks concept
Aging Clocks concept

Aging clocks aim to predict how long you’ll live

These clocks promise to measure biological age and help identify anti-aging drugs, but there are lingering questions over their accuracy.

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.